** Shares of drug developer Cassava Sciences SAVA.O down 85.42% premarket to $3.86, its experimental Alzheimer's disease drug, simufilam, did not meet the main or secondary goals in a late-stage study.
** As a result, Cassava will discontinue a second late-stage study, as well as its open-label study of the drug
** Cassava's shares were halted in premarket hours ahead of the announcement
** Up to the previous session's close, shares were up 17.6% YTD
(Repoting by Joao Manuel Mauricio)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。